Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the Company will report first half 2019 financial results and business highlights on the evening of Thursday, August 22, 2019.
Following the press release, Celyad management will host a conference call on Friday, August 23 at 2pm CEDT / 8am EDT to discuss first half 2019 results and provide an update on the Company’s recent progress and upcoming milestones.
Participants may access the conference call by dialing any of the following numbers:
Belgium, Brussels +32 (0) 24 01 70 35
France, Paris +33 (0)1 76 72 89 28
United States: +1 917 720 0181
International: +44 (0) 2071 928501
Conference ID: 3547725
To access the subsequent archived recording, visit the “Events & Webcasts” section of the Celyad website.
